Flumazenil Reversal of Oral Triazolam
Overview
An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes).
Full Title of Study: “Flumazenil Rescue Strategy”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: December 2007
Interventions
- Drug: Flumazenil
- 2 mL, 0.2 mg SM
- Drug: Placebo
- 2 mL sterile saline SM
Arms, Groups and Cohorts
- Experimental: 1
- Flumazenil 2mL
- Placebo Comparator: 2
- Saline, 2mL SM
Clinical Trial Outcome Measures
Primary Measures
- Observer Assessment of Alertness/Sedation
- Time Frame: 360 minutes
Secondary Measures
- BIS
- Time Frame: 360 minutes
Participating in This Clinical Trial
Inclusion Criteria
- ASA I Exclusion Criteria:
- Use of benzodiazepines, anxiolytics or any other medications that would interact with either triazolam's or flumazenil's metabolism or clinical effect (including herbals) within four weeks of the study – Body mass index (BMI) no less than 15 kg/m2 and no greater than 30 kg/m2 – Pregnancy or not currently using pharmacologic methods of birth control – Allergy or sensitivity to benzodiazepines – History of a seizure disorder; AND – Chronic tobacco use.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 40 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- University of Washington
- Collaborator
- National Institutes of Health (NIH)
- Provider of Information About this Clinical Study
- Peter Milgrom/Professor of Dental Public Health Sciences, University of Washington
- Overall Official(s)
- Peter M Milgrom, DDS, Principal Investigator, University of Washington
References
Jackson DL, Milgrom P, Heacox GA, Kharasch ED. Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers. J Clin Psychopharmacol. 2006 Feb;26(1):4-8. doi: 10.1097/01.jcp.0000186742.07148.da.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.